Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review

Pulmonary arterial hypertension (PAH) remains a progressive disease without a cure, despite the development of several treatment options over the past several decades. Its management strategy consists of the endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Mitchell S, Berry, Andrew J, Kazem, Nadine H, Patel, Shardool A, Librodo, Paul A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073912/
https://www.ncbi.nlm.nih.gov/pubmed/25018685
http://dx.doi.org/10.2147/CE.S50607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073912/
https://www.ncbi.nlm.nih.gov/pubmed/25018685
http://dx.doi.org/10.2147/CE.S50607

Ejemplares similares